

## REMARKS

Claims 1 - 14 are pending. Claims 3 and 5 have been amended. Claims 15 and 16 have been canceled.

Claims 1 and 2 were not rejected and are assumed to be allowed.

Claims 3 - 16 are rejected under 35 U.S.C. 112, first paragraph, because the Examiner asserts that the Specification, while enabling for lowering intraocular pressure, does not reasonably provide enablement for providing neuroprotection. Claims 15 – 16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention because the Examiner the Specification does not teach exactly what compounds can be considered “ $\beta$ -blockers, prostaglandins, carbonic anhydrase inhibitors, miotics, calcium channel blockers and NMDA antagonists.”

In response, Applicants disagree with the Examiner’s assertions about the lack of enablement for the use of the compounds of the present invention as ocular neuroprotectants. Applicants also disagree with the Examiner’s assertion that Claims 15 and 16 are indefinite because the Specification fails to define exactly what compounds are “ $\beta$ -blockers, prostaglandins, carbonic anhydrase inhibitors, miotics, calcium channel blockers and NMDA antagonists.” These classes of compounds are well-recognized classes of compounds to a person of ordinary skill in the art.

Nevertheless, in order to advance prosecution of the remaining claims in this case, Applicants have deleted Claims 15 - 16 and amended Claims 3 and 5 so that the claimed methods do not recite neuroprotection. Accordingly, the 35 U.S.C. 112 rejections are now moot.

Applicant believes that the above amendments and remarks have placed Claims 1 – 14 in condition for allowance. Accordingly, allowance of the claim in this application is respectfully requested.

Respectfully submitted,

ALCON

Date: February 2, 2007

By: /Patrick M. Ryan/  
Patrick M. Ryan  
Reg. No. 36,263

ADDRESS FOR CORRESPONDENCE:  
Alcon Research, Ltd.  
IP Legal TB4-8  
6201 South Freeway  
Fort Worth, TX 76134-2099  
(817) 551-3066

Docket No. 2345